

NAP-2/CXCL7

Catalog # PVGS1217

Product Information

Primary Accession Q99ME0
Species Rat

Sequence Ile46-Ile107

Purity > 97% as analyzed by SDS-PAGE

> 97% as analyzed by HPLC

Endotoxin Level

Biological Activity Fully biologically active when compared to standard. The biologically active

determined by a chemotaxis bioassay using human CXCR2 transfected murine

BaF3 cells is in a concentration range of 0.1-1.0 ng/ml.

Lyophilized from a 0.2 \(\text{Im filtered solution in PBS, pH 7.4.} \)

Expression System E. coli

Theoretical Molecular Weight 6.8 kDa

Formulation

Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to

bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a

concentration of 0.1-1.0 mg/ml.

Storage & Stability Upon receiving, this product remains stable for up to 6 months at -70°C or

-20°C. Upon reconstitution, the product should be stable for up to 1 week at

4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background Neutrophil Activating Peptide 2 (NAP-2) is proteolytically processed

carboxyl-terminal fragments of platelet basic protein (PBP) which is found in the alpha-granules of human platelets. NAP-2 is a member of the CXC chemokines. Similar to other ELR domain containing CXC chemokines such as IL-8 and the GRO proteins, NAP-2 has been shown to bind CXCR-2 and to chemoattract and activate neutrophils. Although CTAP-III, β -TG and PBP represent amino-terminal extended variants of NAP-2 and possess the same CXC chemokine domains, these proteins do not exhibit NAP-2 activity. Recently, it has been shown that the additional amino-terminal residues of

CTAP-III masks the critical ELR receptor binding domain that is exposed on

NAP-2 and may account for lack of NAP-2 activity.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.